Penumbra (PEN) Free Cash Flow Growth (1y) (2015 - 2026)
Penumbra (PEN) Free Cash Flow Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 9.73% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -109.40% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 108.16% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 133.09% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 363.84% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 29.12% |
| 10 | Penumbra | 12.51 Bn | 11.90 Bn | 253.41 Mn | 106.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106.46% |
| Dec 31, 2025 | 27.24% |
| Sep 30, 2025 | 68.11% |
| Jun 30, 2025 | 62.47% |
| Mar 31, 2025 | 9.34% |
| Dec 31, 2024 | 39.40% |
| Sep 30, 2024 | 145.93% |
| Jun 30, 2024 | -7.43% |
| Mar 31, 2024 | 251.61% |
| Dec 31, 2023 | 2,196.49% |
| Sep 30, 2023 | 207.72% |
| Jun 30, 2023 | 144.37% |
| Mar 31, 2023 | 197.51% |
| Dec 31, 2022 | 91.31% |
| Sep 30, 2022 | -156.89% |
| Jun 30, 2022 | -1,208.92% |
| Mar 31, 2022 | 42.78% |
| Dec 31, 2021 | -1,198.07% |
| Sep 30, 2021 | 187.25% |
| Jun 30, 2021 | 88.17% |